Publications by authors named "Rayanna Birtch"
Article Synopsis
- Researchers are exploring ways to improve the effectiveness of oncolytic virotherapy (OV) by modifying innate immunity through genetic and drug strategies.
- They found that vanadium-based compounds, which inhibit phosphatases (PPs), can enhance the oncolytic vesicular stomatitis virus (VSV∆51).
- A targeting approach using short-hairpin RNA (shRNA) against lysosomal acid phosphatase 2 (ACP2) was developed, showing significant increases in viral production and suggesting ACP2's role in regulating antiviral signaling pathways could be key for improving OV treatments.
In recent years, there has been a surge in the innovative modification and application of the viral vector-based gene therapy field. Significant and consistent improvements in the engineering, delivery, and safety of viral vectors have set the stage for their application as RNA interference (RNAi) delivery tools. Viral vector-based delivery of RNAi has made remarkable breakthroughs in the treatment of several debilitating diseases and disorders (e.
View Article and Find Full Text PDFIntroduction: Adipocytes in the tumour microenvironment are highly dynamic cells that have an established role in tumour progression, but their impact on anti-cancer therapy resistance is becoming increasingly difficult to overlook.
Methods: We investigated the role of adipose tissue and adipocytes in response to oncolytic virus (OV) therapy in adipose-rich tumours such as breast and ovarian neoplasms.
Results: We show that secreted products in adipocyte-conditioned medium significantly impairs productive virus infection and OV-driven cell death.